STAT3 is considered to be a promising therapeutic target for a variety of kidney diseases, including diabetic nephropathy, acute kidney injury, lupus nephritis, polycystic kidney disease, and renal cell carcinoma (Bienaimé et al., 2016; Yu et al., 2023). This evidence concerns the gene STAT3 and renal cell carcinoma.